ストックスクリーナーアプリを入手
86.30
0.92%
-0.825
前日終値:
$87.12
開ける：
$86.88
24時間の取引高:
6.37M
Relative Volume:
0.45
時価総額：
$216.30B
収益：
$64.17B
当期純損益:
$17.12B
株価収益率:
12.82
EPS:
6.73
ネットキャッシュフロー:
$18.10B
1週間 パフォーマンス:
-2.04%
1か月 パフォーマンス:
-6.43%
6か月 パフォーマンス:
-22.99%
1年 パフォーマンス:
-33.78%
1日の値動き範囲:
$85.32
$87.07
1週間の範囲:
$85.32
$90.27
52週間の値動き範囲:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
86.31 | 216.30B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
811.82 | 719.11B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
204.15 | 359.93B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
154.80 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
68.36 | 301.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.37 | 216.49B | 51.72B | 11.94B | 13.81B | 5.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. S - GuruFocus
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
The Zacks Analyst Blog Highlights Amazon.com, Oracle and Merck - TradingView
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Top Analyst Reports for Amazon, Oracle & Merck - Yahoo Finance
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein - GlobeNewswire
Merck’s Winrevair Slashes Morbidity-Mortality Risk For PAH Patients - insights.citeline.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck - Bluefield Daily Telegraph
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24 - Business Wire
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
[Latest] Global Semiconductor Specialty Gas Market Size/Share Worth USD 5.34 Billion by 2034 at a 7.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - StreetInsider
Merck & Co., Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Summit Financial LLC Increases Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
MRK Stock Price and Chart — NYSE:MRK - TradingView
MRK Investors Have Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Markets Insider
Why Merck & Co. Inc. (MRK) Went Up On Friday? - Yahoo Finance
Merck Gets Closer To Extending Keytruda Franchise With Subcutaneous Version - insights.citeline.com
Levi & Korsinsky Reminds Merck & Co., Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - ACCESS Newswire
Merck Stock Just Reminded Us Why ‘Buy The Dip’ Is Not That Simple - Barchart
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda - TradingView
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders - ACCESS Newswire
Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher? - Insider Monkey
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
Merck Says Subcutaneous Pembrolizumab Met Primary Endpoints in Phase 3 Trial - Marketscreener.com
Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23 - Marketscreener.com
Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy? - Insider Monkey
Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!” - Yahoo Finance
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook - Seeking Alpha
Merck wins European Commission approval for pneumonia vaccine Capvaxive - Seeking Alpha
Merck & Co. (MRK) Stock: Pharmaceutical Giant Signs $2 Billion Heart Disease Drug Deal - MoneyCheck
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK - TradingView
European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) - Marketscreener.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck Receives European Approval for Streptococcal Pneumonia Vaccine - Marketscreener.com
Merck Gets European Commission Approval of Capvaxive Vaccine - Marketscreener.com
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
0.68%
大文字化:
|
ボリューム (24 時間):